Welcome to Ovoca Bio
Ovoca Bio is a clinical-stage biopharmaceutical company with a focus on women’s health. Founded and incorporated in Ireland, the business currently operates in Ireland and the UK. Ovoca Bio is currently developing Orenetide, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire affecting an estimated ~4 million women in the US with similar patient estimates in Europe. The condition represents a significant area of high unmet medical need with few and challenging treatment options.
Pipeline
Orenetide, a treatment for premenopausal women with hypoactive sexual desire disorder
Our Vision & Approach
Ovoca Bio’s vision is to become a leader in the research and development of, and commercial partner of choice for, novel medicines in areas of high unmet need that affect women.
The Company has filed for approval for the marketing of Oorenetide in US and Europe and has commenced development of the drug for major global markets.
Ovoca Bio will consider opportunities to license commercialisation rights and/or collaborate with global pharmaceutical companies, regional partners or other qualified potential partners where they would accelerate the availability of current plus future product candidates to patients in need.
Ovoca Bio owns a patent portfolio that provides broad effective protection of its technology and lead product candidate. The Company intends to continue to leverage this patent portfolio and selectively add to it, to develop and commercialise its initial product candidate and potentially future ones.